NeuraWorx Partners with Corundum Neuroscience to Initiate Clinical Feasibility Study, Develop Innovative Neurological Disease Treatment
illi News/10276474

EXCELSIOR, Minn. - illiNews -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing System^TM novel technology.

"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."

NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.

"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."

More on illi News

• Deadline Extended: More Time to Submit Your Proposal for the OpenSSL Conference 2025
• Pulitzer Prize Nominated Lauren Coyle Rosen Releases New Album, Covers and Veils in Blue
• Detroit Grand Prix High Profile Media Exposure, $100 Million Financing for Major Acquisition & Growth Strategy; Remote Lottery Platform: Lottery.com
• Tomorrow's World Today Shines Bright with Four Telly Awards at the 46th Annual Telly Awards
• AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.

The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.

"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.

"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.

For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.

About NeuraWorx

NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing System^TM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com

More on illi News

• Chicago: Mayor Brandon Johnson, City Officials, Lamar Johnson Collaborative, and 548 Development Attend Groundbreaking of Mixed-Use West Humboldt Park Development
• ILLINOIS TEAMSTERS DEMAND LAWMAKERS PREVENT CATASTROPHIC CUTS TO PUBLIC TRANSPORTATION
• 6 Love Sports and Eight Sleep Announce Partnership Miami Women's Padel League Rebranded as the Eight Sleep Miami Women's Padel League by 6 Love Sports
• The TOBU RAILWAY X COFFEE PROJECT Supports Nikko Tourism and Fosters English Speaking Guides, Through November 27, 2026
• Al-Tabbaa & Hackett: Fixed Rates Improve For Savers

About Corundum Neuroscience

Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.

For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.